About SpliSense
SpliSense is a company based in Jerusalem (Israel) founded in 2016. SpliSense has raised $41.5 million across 3 funding rounds from investors including Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund. SpliSense offers products and services including SPL84, SPL5AC, SPL5B, and SPL23. SpliSense operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others.
- Headquarter Jerusalem, Israel
- SectorsHealthcare
- Website splisense.com
- Social LinkedIn
- Total Equity Funding$41.5M (USD)
in 3 rounds
- Latest Funding Round$13M (USD), Series B
Jun 2026
- InvestorsOrbimed
& 3 more
Products & Services of SpliSense
SpliSense offers a comprehensive portfolio of products and services, including SPL84, SPL5AC, SPL5B, and SPL23.
Targets cystic fibrosis using ASOs to modify protein function.
Addresses muco-obstructive diseases through RNA-based interventions.
Focuses on pulmonary conditions via Antisense Oligonucleotides.
Develops treatments for additional pulmonary disease opportunities.
Funding Insights of SpliSense
SpliSense has successfully raised a total of $41.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41.5M
- Total Rounds 3
- Last Round Series B — $13M
- First Round $400,000
(Jun 2017)
- Investors Count 4
All 3 funding rounds of SpliSense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $13M | Series B | – | Cystic Fibrosis Foundation | – |
| May 2021 | $28.5M | Series B | – | Cystic Fibrosis Foundation, Orbimed | |
| Jun 2017 | $400,000 | Grant | – | – | – |
4 investors in total: 4 institutional.
Investors in SpliSense
SpliSense has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
- | – | ibf.fund | - | |
Israeli life science ventures are funded by Integra Holdings. | – | integra-holdings.com | Jerusalem, Israel | |
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States |
Investor details for SpliSense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SpliSense
6 people are tracked at SpliSense (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Gili Hart | Chief Executive Officer | Leadership |
Asaf Cohen | VP CMC | Leadership |
Lital Friedman | VP Clinical And Regulatory Affairs | Leadership |
Ilana Bearman | Executive Assistant To CEO | Leadership |
Renana Elgrabli רננה אלגרבלי | Senior Researcher | Team |
Chava Stampfer | Senior Researcher | Team |
Complete people profiles for SpliSense
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SpliSense
3 dated milestones of SpliSense across 10 years, from founding to its latest funding, stage changes and deals.
- Founded SpliSense is founded.
- Funding First funding round of $400K.
- Funding Latest funding round, Series B, of $13.0M.
Competitors of SpliSense
SpliSense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| orgenesis.com | 2008 | Germantown, United States | – | 167 | Cell and gene therapies for multiple disorders are developed. | |
| oribiotech.com | 2015 | London, United Kingdom | $281.12M | 52 | Software development services are provided for the biopharma sector. | |
| masthercell.com | 2011 | Charleroi, Belgium | $17.37M | 329 | Services for cell therapy development and manufacturing are provided. | |
| cognatebioservices.com | 2002 | Hanover, United States | – | 302 | Development and manufacturing services for cell-based therapies are provided. | |
| exmoorpharma.com | 2004 | Bristol, United Kingdom | $51.75M | – | Cell and gene therapeutic services are provided to biopharmaceutical firms. | |
| cell-easy.com | 2015 | Toulouse, France | – | – | Stem cell-based therapy services for research solutions are provided. | |
| obiosh.com | 2013 | Shanghai, China | $87.09M | – | OBiO Technology is engaged in cell and gene therapy solutions. | |
| genflowbio.com | 2020 | Charleroi, Belgium | – | 5 | A biotechnology company focused on anti-aging therapeutics development. |
Detailed competitors of SpliSense
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SpliSense
The website of SpliSense (splisense.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 31.9% vs previous month
Latest news on Splisense
Complete news archive for SpliSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SpliSense
10 companies that operate in the same segment as SpliSense (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SpliSense
SpliSense was founded in 2016 and raised its 1st funding round 1 year after it was founded.
SpliSense is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
SpliSense is a funded company, having raised a total of $41.5M across 3 funding rounds to date. The company's 1st funding round was a Grant of $400K, raised on Jun 2017.
SpliSense was founded in 2016 and is headquartered in Jerusalem, Israel. The companys domain is registered as splisense.com. Limited information is available concerning its industry sector, core operations, or specific services. Details on business activities and geographical scope beyond the founding location are not provided in current records. Further data would be required for a comprehensive overview.
SpliSense's top competitors include Ori Biotech, MaSTherCell and OBiO Technology.
SpliSense offers SPL84, SPL5AC, SPL5B, and SPL23.
SpliSense has 4 investors. Key investors include Orbimed, Cystic Fibrosis Foundation, Israel Biotech Fund, and Integra Holdings.